Patent · US Active

Oligonucleotide compounds for targeting huntingtin mRNA

US9809817B2 · kind B2 · utility

30Cited by
23References
41Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 1, 2016
Grant dateNov 7, 2017
Priority date
Expiry dateApr 1, 2036

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2320/51
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

This disclosure relates to novel huntingtin targets. Novel oligonucleotides for the treatment of Huntington's disease are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.